Targeted combination therapies are associated with higher response rates and delayed progression in patients with HR+, HER2− advanced breast cancer when compared with single-agent endocrine therapy, but this approach can expose patients to additional treatment-related toxicities, which can affect their quality of life (QoL) [7]. Here, ERBB2 is linked to breast cancer.